beta

You're viewing our new website - find out more

Publication - Consultation Paper

Clinical Trial Access quality performance indicator: consultation

Published: 3 Jul 2017
Part of:
Health and social care
ISBN:
9781788510912

Consultation on the effectiveness of the Clinical Trial Access quality performance indicator (QPI) as part of the National Cancer QPIs.

20 page PDF

492.4kB

20 page PDF

492.4kB

Contents
Clinical Trial Access quality performance indicator: consultation
5. Inclusion Criteria

20 page PDF

492.4kB

5. Inclusion Criteria

In order to ensure the most complete and accurate data is available for national comparative reporting, the Clinical Trials QPI Formal Review Group have agreed specific inclusion criteria for the measurement of this QPI:

  • The clinical trials access QPI will be measured for patients with a confirmed cancer diagnosis that aligns to those tumour types with nationally agreed QPIs.
  • Clinical trials must be approved by the National Institute for Health Research ( NIHR) or the Chief Scientist Office ( CSO) as eligible for addition to the UKCRN portfolio. This will incorporate interventional trials, translational research and observational studies. The definition of eligibility for addition to the UKCRN Portfolio [2] is detailed in appendix 4.

Revision(s):

Updated sections 1-4 in line with all formal review QPI documents.

Removed the section on Clinical Trials Definitions.

Added section 5: Inclusion Criteria

Added appendix 4: CSO eligibility for addition to the UKCRN Portfolio


Contact

Email: Chris Booth, chris.booth@gov.scot

Phone: 0300 244 4000 – Central Enquiry Unit

The Scottish Government
St Andrew's House
Regent Road
Edinburgh
EH1 3DG